Citrate and Low-dose Heparin Combined Anticoagulation in Pediatric Continuous Renal Replacement Therapy

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 12

PMID 38866989

Authors

Desheng Zhu

Jie He

Zhenghui Xiao

Xiong Zhou

Xinping Zhang

Affiliations

Soon will be listed here.

Abstract

There remains no optimal anticoagulation protocol for continuous renal replacement therapy (CRRT) with regional citrate anticoagulation (RCA) in pediatric patients with elevated D-dimer levels. We aimed to assess the effects of different anticoagulation strategies on the risk of CRRT filter clotting in these patients. Pediatric patients undergoing CRRT were retrospectively grouped based on pre-CRRT D-dimer levels and anticoagulant: D-RCA group (normal D-dimer, RCA only, n = 22), D+ RCA group (elevated D-dimer, RCA only, n = 50), and D+ RCA+ systemic heparin anticoagulation (SHA) group (elevated D-dimer, RCA combined with SHA, n = 55). The risk of filter clotting and incidence of bleeding were compared among the groups. Among the groups, the D+ RCA+ SHA group had the longest filter lifespan; further, the incidence of bleeding was not increased by concurrent use of low-dose heparin for anticoagulation. Moreover, concurrent heparin anticoagulation was associated with a decreased risk of filter clotting. Contrastingly, high pre-CRRT hemoglobin and D-dimer levels and post-filter ionized calcium level > 0.4 mmol/L were associated with an increased risk of filter clotting. RCA combined with low-dose heparin anticoagulation could reduce the risk of filter clotting and prolong filter lifespan without increasing the risk of bleeding in patients with elevated D-dimer levels undergoing CRRT.

References

Gattas D, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R . A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults. Crit Care Med. 2015; 43(8):1622-9. DOI: 10.1097/CCM.0000000000001004. View

Zarbock A, Kullmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T . Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2020; 324(16):1629-1639. PMC: 7585036. DOI: 10.1001/jama.2020.18618. View

Akhoundi A, Singh B, Vela M, Chaudhary S, Monaghan M, Wilson G . Incidence of Adverse Events during Continuous Renal Replacement Therapy. Blood Purif. 2015; 39(4):333-9. DOI: 10.1159/000380903. View

Wen Y, LeDoux J, Mohamed M, Ramanand A, Scharwath K, Mundy D . Dialysis Filter Life, Anticoagulation, and Inflammation in COVID-19 and Acute Kidney Injury. Kidney360. 2022; 1(12):1426-1431. PMC: 8815528. DOI: 10.34067/KID.0004322020. View

Sun Y, Li D, Bai K, Xu F, Liu C, Dang H . Novel blood product transfusion regimen to prevent clotting and citrate accumulation during continuous renal replacement therapy with regional citrate anticoagulation in children. Front Pediatr. 2023; 11:1086420. PMC: 10310529. DOI: 10.3389/fped.2023.1086420. View

Al-Dorzi H, Alhumaid N, Alwelyee N, Albakheet N, Nazer R, Aldakhil S . Anemia, Blood Transfusion, and Filter Life Span in Critically Ill Patients Requiring Continuous Renal Replacement Therapy for Acute Kidney Injury: A Case-Control Study. Crit Care Res Pract. 2019; 2019:3737083. PMC: 6369504. DOI: 10.1155/2019/3737083. View

Onishi A, St Ange K, Dordick J, Linhardt R . Heparin and anticoagulation. Front Biosci (Landmark Ed). 2016; 21(7):1372-92. DOI: 10.2741/4462. View

Li R, Gao X, Zhou T, Li Y, Wang J, Zhang P . Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: A meta-analysis of randomized controlled trials. Ther Apher Dial. 2022; 26(6):1086-1097. DOI: 10.1111/1744-9987.13850. View

Tsang D, Tuckfield A, MacIsaac C . Audit of safety and quality of the use of enoxaparin for anticoagulation in continuous renal replacement therapy. Crit Care Resusc. 2011; 13(1):24-7. View

10.

Zhou Z, Liu C, Yang Y, Wang F, Zhang L, Fu P . Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care. 2023; 27(1):222. PMC: 10249230. DOI: 10.1186/s13054-023-04519-1. View

11.

Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M . Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020; 12:CD012467. PMC: 8812343. DOI: 10.1002/14651858.CD012467.pub3. View

12.

James M, Bouchard J, Ho J, Klarenbach S, Lafrance J, Rigatto C . Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013; 61(5):673-85. DOI: 10.1053/j.ajkd.2013.02.350. View

13.

Wells P, Anderson D, Rodger M, Forgie M, Kearon C, Dreyer J . Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003; 349(13):1227-35. DOI: 10.1056/NEJMoa023153. View

14.

Dunn W, Sriram S . Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables. Crit Care Resusc. 2014; 16(3):225-31. View

15.

Raina R, Sethi S, Khooblall A, Kher V, Deshpande S, Yerigeri K . Non-anticoagulation pediatric continuous renal replacement therapy methods to increase circuit life. Hemodial Int. 2022; 26(2):147-159. DOI: 10.1111/hdi.13003. View

16.

Du Cheyron D, Parienti J, Fekih-Hassen M, Daubin C, Charbonneau P . Impact of anemia on outcome in critically ill patients with severe acute renal failure. Intensive Care Med. 2005; 31(11):1529-36. DOI: 10.1007/s00134-005-2739-5. View

17.

Haga T, Ide K, Tani M . Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan. Ther Apher Dial. 2022; 27(3):562-570. DOI: 10.1111/1744-9987.13958. View

18.

Valle E, Cabrera C, Albuquerque C, Silva G, de Oliveira M, Sales G . Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study. Crit Care. 2021; 25(1):299. PMC: 8375288. DOI: 10.1186/s13054-021-03729-9. View

19.

Connors J, Levy J . COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135(23):2033-2040. PMC: 7273827. DOI: 10.1182/blood.2020006000. View

20.

Brain M, Winson E, Roodenburg O, McNeil J . Non anti-coagulant factors associated with filter life in continuous renal replacement therapy (CRRT): a systematic review and meta-analysis. BMC Nephrol. 2017; 18(1):69. PMC: 5319031. DOI: 10.1186/s12882-017-0445-5. View